Leiden, The Netherlands, February 15, 2008. Biotech company Pharming Group NV ("Pharming" or "the Company") (Euronext: PHARM) announced today its financial results (unaudited) for the year ending 31 December, 2007. The Company has strengthened its cash position and has made significant progress in the development of Rhucin® (recombinant human C1 inhibitor or rhC1INH for treatment of acute attacks of Hereditary Angioedema or HAE).
